HtrA1 sensitizes ovarian cancer cells to cisplatin-induced cytotoxicity by targeting XIAP for degradation

International Journal of Cancer

Volumn 130, Issue 5, 2012, Pages 1029-1035

  He, Xiaoping ^a   Khurana, Ashwani ^a   Maguire, Jacie L ^a   Chien, Jeremy ^a   Shridhar, Viji ^a  

^a Mayo Clinic College of Medicine   (United States)

Author keywords

apoptosis; chemoresistance; HtrA1; ovarian cancer; XIAP

Indexed keywords

CISPLATIN; HTRA1 PROTEIN; RECOMBINANT X LINKED INHIBITOR OF APOPTOSIS; SERINE PROTEINASE; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; ARTICLE; CANCER RESISTANCE; COMPLEX FORMATION; CONTROLLED STUDY; DRUG SENSITIZATION; DRUG TARGETING; ENZYME SUBSTRATE; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; OVARY CANCER; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PURIFICATION; WILD TYPE;

ANTINEOPLASTIC AGENTS; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; OVARIAN NEOPLASMS; RECOMBINANT PROTEINS; SERINE ENDOPEPTIDASES; TUMOR CELLS, CULTURED; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 84155172509     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26044     Document Type: Article

References (33)

1. Chien JR, Aletti G, Bell DA, Keeney GL, Shridhar V, Hartmann LC,. Molecular pathogenesis and therapeutic targets in epithelial ovarian cancer. J Cell Biochem 2007; 102: 1117-29. (Pubitemid 350220033)
2. Chobanian N, Dietrich CS, III,. Ovarian cancer. Surg Clin North Am 2008; 88: 285-99, vi. (Pubitemid 351434416)
3. Clausen T, Southan C, Ehrmann M,. The HtrA family of proteases: implications for protein composition and cell fate. Molecular cell 2002; 10: 443-455. (Pubitemid 35284166)
4. Chien J, He X, Shridhar V,. Identification of tubulins as substrates of serine protease HtrA1 by mixture-based oriented peptide library screening. J Cell Biochem 2009; 107: 253-63.
5. Chien J, Campioni M, Shridhar V, Baldi A,. HtrA serine proteases as potential therapeutic targets in cancer. Curr Cancer Drug Targets 2009; 9: 451-68.
6. Chien J, Staub J, Hu SI, Erickson-Johnson MR, Couch FJ, Smith DI, Crowl RM, Kaufmann SH, Shridhar V,. A candidate tumor suppressor HtrA1 is downregulated in ovarian cancer. Oncogene 2004; 23: 1636-44. (Pubitemid 38406528)
7. Chien J, Aletti G, Baldi A, Catalano V, Muretto P, Keeney GL, Kalli KR, Staub J, Ehrmann M, Cliby WA, Lee YK, Bible KC, et al. Serine protease HtrA1 modulates chemotherapy-induced cytotoxicity. J Clin Invest 2006; 116: 1994-2004. (Pubitemid 44033323)
8. Schimmer AD, Dalili S, Batey RA, Riedl SJ,. Targeting XIAP for the treatment of malignancy. Cell Death Differ 2006; 13: 179-88. (Pubitemid 43102202)
9. Shaw TJ, Lacasse EC, Durkin JP, Vanderhyden BC,. Downregulation of XIAP expression in ovarian cancer cells induces cell death in vitro and in vivo. Int J Cancer 2008; 122: 1430-4. (Pubitemid 351287247)
10. Ding X, Mohd AB, Huang Z, Baba T, Bernardini MQ, Lyerly HK, Berchuck A, Murphy SK, Buermeyer AB, Devi GR,. MLH1 expression sensitises ovarian cancer cells to cell death mediated by XIAP inhibition. Br J Cancer 2009; 101: 269-77.
11. Li J, Feng Q, Kim JM, Schneiderman D, Liston P, Li M, Vanderhyden B, Faught W, Fung MF, Senterman M, Korneluk RG, Tsang BK,. Human ovarian cancer and cisplatin resistance: possible role of inhibitor of apoptosis proteins. Endocrinology 2001; 142: 370-80. (Pubitemid 32183698)
12. Ma JJ, Chen BL, Xin XY,. XIAP gene downregulation by small interfering RNA inhibits proliferation, induces apoptosis, and reverses the cisplatin resistance of ovarian carcinoma. Eur J Obstet Gynecol Reprod Biol 2009; 146: 222-6.
13. He X, Ota T, Liu P, Su C, Chien J, Shridhar V,. Downregulation of HtrA1 promotes resistance to anoikis and peritoneal dissemination of ovarian cancer cells. Cancer Res 2010; 70: 3109-18.
14. Ndozangue-Touriguine O, Sebbagh M, Mérino D, Micheau O, Bertoglio J, Bréard J,. A mitochondrial block and expression of XIAP lead to resistance to TRAIL-induced apoptosis during progression to metastasis of a colon carcinoma. Oncogene 2008; 27: 6012-22.
15. Fraser M, Leung B, Jahani-Asl A, Yan X, Thompson WE, Tsang BK,. Chemoresistance in human ovarian cancer: the role of apoptotic regulators. Reprod Biol Endocrinol 2003; 1: 66-79.
16. Eckelman BP, Salvesen GS, Scott FL,. Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family. EMBO Rep 2006; 7: 988-94. (Pubitemid 44480512)
17. Srinivasula SM, Ashwell JD,. IAPs: what's in a name? Mol Cell 2008; 30: 123-35. (Pubitemid 351626688)
18. Sapi E, Alvero AB, Chen W, O'Malley D, Hao XY, Dwipoyono B, Garg M, Kamsteeg M, Rutherford T, Mor G,. Resistance of ovarian carcinoma cells to docetaxel is XIAP dependent and reversible by phenoxodiol. Oncol Res 2004; 14: 567-78. (Pubitemid 40178958)
19. Mansouri A, Zhang Q, Ridgway LD, Tian L, Claret FX,. Cisplatin resistance in an ovarian carcinoma is associated with a defect in programmed cell death control through XIAP regulation. Oncol Res 2003; 13: 399-404. (Pubitemid 38166371)
20. Sasaki H, Sheng Y, Kotsuji F, Tsang BK,. Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells. Cancer Res 2000; 60: 5659-66.
21. Vaux DL, Silke J,. Mammalian mitochondrial IAP binding proteins. Biochem Biophys Res Commun 2003; 304: 499-504. (Pubitemid 36506522)
22. Wu G, Chai J, Suber TL, Wu JW, Du C, Wang X, Shi Y,. Structural basis of IAP recognition by Smac/DIABLO. Nature 2000; 408: 1008-12. (Pubitemid 32101651)
23. Verhagen AM, Ekert PG, Pakusch M, Silke J, Connolly LM, Reid GE, Moritz RL, Simpson RJ, Vaux DL,. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 2000; 102: 43-53.
24. Suzuki Y, Takahashi-Niki K, Akagi T, Hashikawa T, Takahashi R,. Mitochondrial protease Omi/HtrA2 enhances caspase activation through multiple pathways. Cell Death Differ 2004; 11: 208-16. (Pubitemid 38159645)
25. Yang QH, Church-Hajduk R, Ren J, Newton ML, Du C,. Omi/HtrA2 catalytic cleavage of inhibitor of apoptosis (IAP) irreversibly inactivates IAPs and facilitates caspase activity in apoptosis. Genes Dev 2003; 17: 1487-96. (Pubitemid 36734706)
26. Srinivasula SM, Gupta S, Datta P, Zhang Z, Hegde R, Cheong N, Fernandes-Alnemri T, Alnemri ES,. Inhibitor of apoptosis proteins are substrates for the mitochondrial serine protease Omi/HtrA2. J Biol Chem 2003; 278: 31469-72. (Pubitemid 37048322)
27. Cilenti L, Kyriazis GA, Soundarapandian MM, Stratico V, Yerkes A, Park KM, Sheridan AM, Alnemri ES, Bonventre JV, Zervos AS,. Omi/HtrA2 protease mediates cisplatin-induced cell death in renal cells. Am J Physiol Renal Physiol 2005; 288: F371-9. (Pubitemid 40105396)
28. Pruefer FG, Lizarraga F, Maldonado V, Melendez-Zajgla J,. Participation of Omi Htra2 serine-protease activity in the apoptosis induced by cisplatin on SW480 colon cancer cells. J Chemother 2008; 20: 348-54. (Pubitemid 351998897)
29. Carter BZ, Mak DH, Morris SJ, Borthakur G, Estey E, Byrd AL, Konopleva M, Kantarjian H, Andreeff M,. XIAP antisense oligonucleotide (AEG35156) achieves target knockdown and induces apoptosis preferentially in CD34(+)38 (-) cells in a phase 1/2 study of patients with relapsed/refractory AML. Apoptosis 2011; 16: 67-74.
30. Kim DW, Kim KO, Shin MJ, Ha JH, Seo SW, Yang J, Lee FY,. siRNA-based targeting of antiapoptotic genes can reverse chemoresistance in P-glycoprotein expressing chondrosarcoma cells. Mol Cancer 2009; 8: 28-38.
31. Shrikhande SV, Kleeff J, Kayed H, Keleg S, Reiser C, Giese T, Büchler MW, Esposito I, Friess H,. Silencing of X-linked inhibitor of apoptosis (XIAP) decreases gemcitabine resistance of pancreatic cancer cells. Anticancer Res 2006; 26: 3265-73. (Pubitemid 44701495)
32. Schimmer AD, Estey EH, Borthakur G, Carter BZ, Schiller GJ, Tallman MS, Altman JK, Karp JE, Kassis J, Hedley DW, Brandwein J, Xu W, et al. Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia. J Clin Oncol 2009; 27: 4741-6.
33. Lecis D, Drago C, Manzoni L, Seneci P, Scolastico C, Mastrangelo E, Bolognesi M, Anichini A, Kashkar H, Walczak H, Delia D,. Novel SMAC-mimetics synergistically stimulate melanoma cell death in combination with TRAIL and Bortezomib. Br J Cancer 2010; 102: 1707-16.